Our study explores the expression of immune checkpoint biomarkers TIGIT, LAG-3, and PD-L1 across molecular subtypes of MIBC.<h4>Methods</h4>Immunohistochemical analysis was performed on archival tumor samples from 62 patients, evenly split between luminal and basal molecular MIBC subtypes.<h4>Results</h4>The findings revealed that luminal MIBC patients with high stromal LAG-3 expression had significantly worse survival outcomes compared to those with the basal subtype, establishing LAG-3 as an independent prognostic marker of poor survival in luminal MIBC. The gene discussed is TIGIT; the disease is neoplasm.